Search Results
Your search for it matches 15610 pages
Showing 2351 - 2400Study Analyzes Postimaging Diagnoses of Pancreatic Cancer
Computed tomography (CT) and magnetic resonance imaging (MRI) scans may miss the detection of some pancreatic cancer tumors, narrowing the window for life-saving curative surgery, according to new research presented at the United European Gastroenterology (UEG) Week 2022 (Abstract OP192). The...
Sandra L. Wong, MD, on Severe Symptom Reporting in Patients With Cancer Who Have Undergone Surgery
Sandra L. Wong, MD, of the Dartmouth-Hitchcock Medical Center, discusses her study findings showing that when patients with cancer who have had surgery reported severe symptoms via an electronic patient-reported outcomes questionnaire at six cancer centers, it appeared to be beneficial without...
Expert Point of View: James Larkin, PhD and Andrea Cercek, MD
Invited discussant James Larkin, PhD, a clinical researcher at the Royal Marsden Hospital, London, commented on the findings from NICHE-2.1 “These striking data are consistent with the recent report in locally advanced mismatch repair–deficient [dMMR] rectal cancer from Memorial Sloan Kettering.2...
NICHE-2: ‘Unprecedented’ Waterfall Plot Achieved With Neoadjuvant Immunotherapy in dMMR Colon Cancer
Treatment with neoadjuvant immunotherapy in colon cancer resulted in major pathologic responses in 95% of patients, NICHE-2 investigators reported at the European Society for Medical Oncology (ESMO) Congress 2022.1 Additionally, after 4 weeks of nivolumab plus ipilimumab, 67% of patients with...
Decrease in Breast Cancer Mortality Rate Continues, but Gap Persists for Black Women: From American Cancer Society Report
Although breast cancer death rates dropped by 43% from 1989 to 2020, Black women continue to be 40% more likely to die of the disease, despite a lower incidence, according to findings outlined in the American Cancer Society’s report Breast Cancer Statistics, 2022, and a companion study published by ...
Cancer Care and Reproductive Health Resources for the Oncology Community
On June 24, 2022, the U.S. Supreme Court announced its decision in Dobbs v Jackson Women’s Health Organization, effectively eliminating the constitutional right to abortion and returning the power to regulate reproductive health to individual states. Some states have already taken action to...
ASCO and the African Organisation for Research and Training in Cancer Announce Innovative Collaboration to Advance Cancer Research in Africa
ASCO and the African Organisation for Research and Training in Cancer (AORTIC) have signed a memorandum of understanding (MOU) committing the two organizations to collaborate to advance cancer research in Africa. Harnessing the respective programs, leaders, and member networks of both...
Ibrutinib for Pediatric Patients With Chronic Graft-vs-Host Disease
On August 24, 2022, ibrutinib was approved for pediatric patients 1 year of age or older with chronic graft-vs-host disease after failure of one or more lines of systemic therapy.1 A new oral suspension formulation is available. Supporting Efficacy Data Approval was based on findings from the...
Managing Lymphomas in the Future: Some Bright Spots Are Emerging
Although standard therapies may provide long-lasting remissions for many patients with various subtypes of lymphoma, there is a critical need for new strategies for the sizable high-risk subset. At the 2022 Pan Pacific Lymphoma Conference, four experts in the field described future therapies for...
Vanderbilt University Medical Center Selects New Director of the Division of Infectious Diseases
Kelly Dooley, MD, PhD, MPH, has been appointed Addison B. Scoville Jr. Professor of Medicine and Director of the Division of Infectious Diseases in the Department of Medicine at Vanderbilt University Medical Center (VUMC). Dr. Dooley comes to Vanderbilt from The Johns Hopkins School of Medicine in...
Expert Point of View: Jonathan Ledermann, MD
Jonathan Ledermann, MD, of UCL Cancer Institute University College London, was the formal discussant of both the phase III SOLO1 and PAOLA-1 trials. He was quite enthusiastic about SOLO1: “Perhaps, this is really cure we are seeing.” He also noted that overall survival is still immature and is...
First-Line Maintenance With Olaparib Improved Overall Survival in Subsets of Patients With Advanced Ovarian Cancer in Two Phase III Trials
First-line maintenance therapy with olaparib extended survival beyond historical expectations in some women with newly diagnosed advanced ovarian cancer, according to two phase III studies presented at the European Society for Medical Oncology (ESMO) 2022 Congress.1,2 In the SOLO1 trial,1 more...
TROPiCS-02: Sacituzumab Govitecan Improves Overall Survival in Hormone Receptor–Positive, HER2-Negative Breast Cancer
An overall survival benefit has now emerged for sacituzumab govitecan-hziy in women with previously treated, hormone receptor–positive/HER2-negative, locally recurrent, inoperable or metastatic breast cancer, according to a planned second interim analysis of the phase III TROPiCS-02 trial.1 The...
Expert Point of View: Suzette Delaloge, MD, MSc
Formal discussant of this study, Suzette Delaloge, MD, MSc, of Gustave Roussy, Villejuif, France, stated: “This is a big step forward and an amazing set of new knowledge. This presentation is a meaningful demonstration of the role of PM2.5 [particulate matter 2.5 µm in diameter] air pollutants in...
Mechanism Linking Air Pollution to Lung Cancer Identified
Although air pollution is associated with lung cancer, not much has been known about how one leads to the other. For the first time, researchers have identified a mechanism by which particulate matter in the air triggers non–small cell lung cancer (NSCLC) in people who have never smoked. Moreover,...
What Is the Best Induction Regimen for Newly Diagnosed PCNSL?
Primary central nervous system lymphoma (PCNSL) accounts for less than 1% of all non-Hodgkin lymphomas and between 3% and 4% of all brain tumors, with an age-adjusted incidence rate of four cases per million persons per year. Approximately 1,500 new cases are diagnosed each year in the United...
Cancer and Fertility Preservation: Will New Laws Leave Patients Without Options?
The legal climate surrounding reproductive health care and fertility preservation has changed drastically since the June 2022 Supreme Court decision to overturn Roe v Wade, which revoked the constitutional right to abortion. With this ruling, individual state legislatures are now able to pass laws...
Expert Point of View: Alexander M.M. Eggermont, MD; Omid Hamid, MD; and James Larkin, PhD
The results of SWOG S18011 were met with enthusiasm by attendees at the Presidential Symposium of the European Society for Medical Oncology (ESMO) Congress 2022. The ASCO Post captured the thoughts of several melanoma experts, who had somewhat different ideas about the immediate clinical...
SWOG S1801: Addition of Neoadjuvant Pembrolizumab to Adjuvant Pembrolizumab Yields Benefits in High-Risk Resectable Melanoma
In resectable stage III to IV melanoma, three cycles of neoadjuvant pembrolizumab followed by adjuvant pembrolizumab was significantly more beneficial than adjuvant pembrolizumab alone, based on the results of the phase II SWOG S1801 trial presented in a Presidential Symposium at the European...
Saul A. Rosenberg, MD, FASCO, a Pioneer in the Field of Lymphoma, Dies at 95
For anacademic oncologist, there is no greater reward than to be part of the clinical research that turns a fatal cancer into a highly treatable disease. Saul A. Rosenberg, MD, FASCO, was one such researcher who pioneered advances in the diagnosis, treatment, and understanding of lymphoma,...
Living With Metastatic Breast Cancer
After my first breast cancer diagnosis, in 2010, the odds for a cure were seemingly all weighted in my favor. A routine mammogram screening had picked up a small—less than 1 cm—mass in my right breast, and a tissue biopsy confirmed it was stage I estrogen receptor–positive breast cancer. I had no...
The Development of Geriatric Oncology in France: An Outside View
With the aging of the world population, geriatric oncology is becoming a mainstay. Over the past year in The ASCO Post, we published a couple of articles on the history of oncology, including one on the history of geriatric oncology in the United States and Europe. Our goal was to promote a...
Darolutamide Combined With Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
On August 5, 2022, darolutamide was approved for use in combination with docetaxel for patients with metastatic hormone-sensitive prostate cancer.1 Approval was based on the double-blind ARASENS trial (ClinicalTrials.gov identifier NCT02799602), in which 1,305 patients were randomly assigned to...
Update on the Impact of the Russian Invasion of Ukraine on Patients With Cancer
In the more than 7 months since Russia invaded Ukraine on February 24, 2022, cancer care for Ukrainian citizens has changed dramatically. Ukraine was once a country able to provide its approximately 160,000 newly diagnosed patients with cancer each year with modern diagnostic methods, including...
New Study Highlights Sexual Problems Among Young Women Who Have Had Cancer
Young women who are cancer survivors may be at a much higher risk of sexual problems, including loss of libido and discomfort, according to research published by Wettergren et al in the journal Acta Oncologica. The study also suggests that cancer type and intensity of treatment may influence the...
Research Examines a New Tool for Discovering Cancer-Driving Structural Variations
An advanced software tool for analyzing DNA sequences from tumor samples has uncovered new, likely cancer-driving genes. In a study, Weill Cornell Medicine researchers designed the software, known as CSVDriver, to map and analyze the locations of large mutations, known as structural variants, in...
Expert Point of View: Benjamin Besse, MD, PhD
Discussant of the IMpower010 abstract, Benjamin Besse, MD, PhD, Professor and Head of Clinical Research at Institute Gustave Roussy, Villejuif, France, said there is enough evidence to use adjuvant immunotherapy in stage II–IIIA resected non–small cell lung cancer (NSCLC), calling the increased...
Study Finds High-Intensity Intervention Helped One-Third of Participants in Lung Cancer Screening Program to Quit Smoking
Despite significant advancements in cancer therapy, the number-one stopper of lung cancer remains the most basic intervention: quitting smoking. Unfortunately, for long-term smokers, that intervention can sometimes be the most challenging. According to data presented during the International...
Highlights From the IASLC 2022 World Conference on Lung Cancer
Over the past few years, we have seen rapid and dramatic transformation in the therapeutic landscape of non–small cell lung cancer (NSCLC). We have had multiple new targeted therapies for newer targets (previously undruggable targets) and better diagnostic strategies to workup patients to realize...
Expert Point of View: Anand Devaraj, MD, PhD
Abstract discussant Anand Devaraj, MD, PhD, Professor in Thoracic Radiology at Royal Brompton and Harefield Hospitals, and Professor of Thoracic Radiology at the National Heart and Lung Institute, Imperial College London, highlighted the increased risk of second primary tumors among current...
Expert Point of View: Corinne Faivre-Finn, MD, PhD, and Masahiro Tsuboi, MD
The first discussant of the NADIM II study, Corinne Faivre-Finn, MD, PhD, Professor of Thoracic Radiation Oncology, University of Manchester, and Honorary Consultant Clinical Oncologist at The Christie NHS Foundation Trust, Manchester, England, called the results “very impressive” but noted that...
Expert Point of View: Chia Puey Ling, MBBS, MMed, MRCP, FRACP, PhD
Discussant of the exploratory analysis of the POSEIDON trial, Chia Puey Ling, MBBS, MMed, MRCP, FRACP, PhD, a medical oncologist at Tan Tock Seng Hospital, Singapore, noted that although 30% of the mutation-evaluable population had KRAS mutations, only a small percentage of patients had co-mutated...
Researchers Identify Potential Biomarker to Distinguish Group 3 and Group 4 Medulloblastomas
It may soon be possible to identify group 4 medulloblastomas from more aggressive group 3 tumors. Research based on a little-explored part of RNA that creates proteins may lead to the development of better-targeted therapies, according to investigators at the Johns Hopkins Kimmel Cancer Center....
Extended-Interval vs Standard-Interval Dosing of Single-Agent Pembrolizumab
In a retrospective cohort study performed in U.S. veterans reported in JAMA Oncology, Strohbehn et al found that a minority of patients receiving singe-agent pembrolizumab for cancer received the extended-interval dosing of 400 mg every 6 weeks. Analysis of efficacy measured as the time to...
Expert Point of View: Jean-Yves Blay, MD, PhD
The invited discussant of the DeFi trial was Jean-Yves Blay, MD, PhD, General Director of the Center Bérard, Lyon, France, and President of Unicancer, the French Federation of Cancer Centers. He called the DeFi study a “rigorous trial” in a “representative population” that “introduces a new class...
DeFi Trial: Novel Gamma Secretase Inhibitor Halts Progression of Desmoid Tumors
Patients with rare desmoid tumors may finally have an effective treatment. A first-in-class gamma secretase inhibitor, nirogacestat, led to an improvement in progression-free survival in the phase III DeFi trial. The results were presented during the Presidential Symposium at the European Society...
Tissue vs ctDNA NGS for Detecting Actionable Alterations in Patients With Advanced Cancer
A large prospective analysis, published by Bayle et al in Annals of Oncology, evaluated differences between tissue and circulating tumor DNA (ctDNA) next-generation sequencing (NGS) with a large cancer gene panel. The investigators compared the impacts of both methods in terms of molecular tumor...
Genetic Variation May Explain Racial Disparity in Esophageal Cancer Cases
Esophageal adenocarcinoma is a type of cancer affecting the mucus-secreting glands of the lower esophagus and is the most common form of esophageal cancer. It is often preceded by Barrett’s metaplasia, a deleterious change in cells lining the esophagus. Though the cause of esophageal adenocarcinoma ...
Lasker Foundation Announces 2022 Lasker Award Winners
On September 28, the Lasker Foundation announced the winners of the 2022 Albert Lasker Basic Medical Research Award, the 2022 Lasker~DeBakey Clinical Medical Research Award, and the 2022 Lasker~Bloomberg Public Service Award. Albert Lasker Basic Medical Research Award Richard O. Hynes, PhD, of the...
Financial Burden of High-Cost Targeted Oral Anticancer Drugs Among Medicare Patients
In a study reported in JCO Oncology Practice, Li et al identified elements of increasing financial burden associated with the use of high-cost targeted oral anticancer drugs among Medicare patients between 2011 and 2016. The study used data from the Surveillance, Epidemiology, and End Results...
Unhealthy Gut May Set the Stage for Breast Cancer to Spread, Preclinical Research Reveals
An unhealthy gut triggers changes in normal breast tissue that may help breast cancer metastasize, according to new, early research from the University of Virginia (UVA) Cancer Center published by Feng et al in Cancer Immunology Research. The researchers found that when the gut microbiome is...
Research Finds Medicaid Expansion Led to Decreases in Cancer Incidence and Mortality Rates
State-run Medicaid insurance, expanded in 2014 as part of the Affordable Care Act, has resulted in decreased metastatic cancer incidence rates as well as decreased overall cancer mortality rates, and has averted over 1,000 deaths due to cancer per year. About 12% of the improvements in cancer...
Can a Navigation Program Lower Care Costs for Patients With Cancer?
A cancer navigation program can reduce overall costs when deployed in collaboration with a statewide Medicare Advantage health plan across a wide range of practice types, according to findings to be presented by Worland et al at the upcoming 2022 ASCO Quality Care Symposium (Abstract 4). A...
Total Cost of Cancer Care May Be Reduced With Lower-Cost Alternate Drugs Without Compromising Quality of Care
Substituting biosimilars, generics, and clinically appropriate lower-cost drugs for established, costlier drugs was shown to be an effective way to reduce the total cost of care, by 5% or so, while maintaining the quality of care for patients with cancer. Even small shifts toward lower-cost drugs...
A Physicist Father Inspired a Love of Science in Oncology Researcher Stanton L. Gerson, MD
In this installment of the Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Stanton (“Stan”) L. Gerson, MD, Dean and Senior Vice President for Medical Affairs, School of Medicine, and Acting Director of the Case Comprehensive Cancer Center and National Center for...
Changing the Algorithm for Relapsed or Refractory Large B-Cell Lymphomas
Despite a significant potential for cure, relapsed and refractory large B-cell lymphomas (LBCL) comprise the most common cause of lymphoma-related mortality. Sequential relapses reflect the limits of repeated exposure to chemotherapy, even when delivered at high doses. More than 30 years ago,...
Diversify Cancer Clinical Trials With New Recruitment and Retention Resources
ASCO and the Association of Community Cancer Centers (ACCC) jointly released two resources to help research sites increase racial and ethnic equity, diversity, and inclusion (EDI) in cancer clinical trials. The Just ASK™ Increasing Diversity in Cancer Clinical Research: An ACCC-ASCO Training...
Determining Prognosis in Aggressive Lymphomas: Integrating Liquid Biopsy Into Imaging Assessment
The incorporation of blood-based measurements—ie, “liquid biopsies”—into imaging assessment may refine the accuracy of prognosis in aggressive lymphomas, as described by David Kurtz, MD, PhD, Assistant Professor in the Division of Oncology, Stanford University Medical Center, in a talk at the 2022...
Expert Point of View: Chia Puey Ling, MBBS, MMed, MRCP, FRACP, PhD
Discussant of the exploratory analysis of the POSEIDON trial, Chia Puey Ling, MBBS, MMed, MRCP, FRACP, PhD, a medical oncologist at Tan Tock Seng Hospital, Singapore, noted that although 30% of the mutation-evaluable population had KRAS mutations, only a small percentage of patients had co-mutated...
Geriatric Oncology and Hematology in Singapore
Globally, the population is aging, with the number of people aged 60 and older projected to double from 1 billion worldwide in 2020 to 2.1 billion by 2050. Given the aging population, coupled with the risk of cancer increasing with age, an exponential rise in cases of older adults diagnosed with...
